New strategies for profound inhibition of platelet activity at the injured coronary plaque focus on blockade of the platelet surface membrane glycoprotein IIb/IIIa receptor, which binds circulating fibrinogen or von Willebrand factor and crosslinks platelets as the final common pathway to platelet aggregation. Intravenous agents directed against this receptor include the chimeric monoclonal ant...

BACKGROUND AND PURPOSE To evaluate preliminarily efficacy and safety of intravenous tirofiban combined with mechanical clot disruption and urokinase in patients with stroke attributable to major cerebral artery occlusion. METHODS Eleven consecutive patients with stroke attributable to acute occlusion of a major cerebral artery were treated with an intravenous bolus injection of the platelet g...

BACKGROUND Thrombocytopenia is a possible complication of treatment with glycoprotein (GP) IIb/IIIa antagonists during percutaneous coronary interventions, but it is not clear whether different GP IIb/IIIa inhibitors carry a different risk of thrombocytopenia, and its relation to clinical outcome is unknown. METHODS AND RESULTS We analyzed data from the Do Tirofiban and Reopro Give Similar Ef...

OBJECTIVES We examined the lytic effects of anti-glycoprotein (GP) IIb/IIIa agents on platelet thrombi formed on the collagen surface under blood flow conditions. BACKGROUND Anti-GP IIb/IIIa agents may influence platelet thrombi already formed. METHODS Blood samples were anticoagulated either by the specific antithrombin Argatroban (100 microM) or by unfractionated heparin (0.1 U/ml). After...

BACKGROUND There is some controversy as to whether tirofiban or eptifibatide, two small anti-aggregating drugs (AAD), may reduce the incidence of composite ischemic events within one year in patients undergoing percutaneous coronary intervention (PCI) in the real clinical world. METHODS We compared consecutive patients on oral double AAD (with clopidogrel and aspirin) who underwent PCI (n=207...

Background: Lacunar ischemic infarcts are small-sized that develop as a result of occlusion perforating arteries. Although its pathophysiology differs from other stroke types, there is no separate treatment option non-cardioembolic strokes. Early neurological worsening in lacunar strokes common condition reported up to 41%. There effective method prevent or correct progression. Tirofiban revers...

Objective: The aim of this study was to investigate the antithrombotic effect and safety of Bivalirudin compared with heparin plus Tirofiban in elderly patients with acute myocardial infarction undergoing primary Percutaneous Coronary Intervention (PCI). Methods: One hundred and twenty elderly patients were randomly assigned to receive two different antithrombotic therapies (Group A: Bivalirudi...

Inhibitor Therapy To the Editor: In their clinically sound GOLD (AU-Assessing Ultegra) study, Steinhubl et al1 reported striking results concerning the widely variable level of platelet function inhibition achieved with glycoprotein IIb/IIIa (GP IIb/IIIa) antagonists among patients undergoing percutaneous coronary intervention. They also documented the important clinical implications related to...

Pulmonary hemorrhage following percutaneous coronary intervention is a very rare complication that has been previously reported in association with abciximab and tirofiban, but not with clopidogrel. We report the case of a 56-year-old man who developed diffuse alveolar hemorrhage after receiving clopidogrel for placement of a coronary stent. Since clopidogrel is a commonly used medication, clin...

From the Department of Cardiology, Apollo Hospital, 21, Greams Lane, Off Greams Road, Chennai 600006, India. Drs. Sengottuvelu and Rajendran have reported that they have no relationships relevant to the intravenous tirofiban infusion along with oral antiplatelets. A check angiogram after 4 days showed mild clearing of the filling defects (Fig. 1B, Online Video 2). Optical coherence tomography r...